Cardiovascular disease remains the world’s biggest killer, responsible for nearly 18 million deaths each year, according to the World Health Organisation. For investors, it is also one of the most enduring areas of healthcare spending — spanning pharmaceuticals, diagnostics and medical devices that together make up a multibillion-dollar market.
Yet despite the sheer size of the opportunity, cardiovascular innovation often receives less attention than hot-button areas like oncology or neuroscience. But with populations ageing rapidly, pressure on hospital systems mounting, and device technology entering a new phase, heart health is moving back to the centre of biotech’s investment conversation.
The growing burden of structural heart disease
Among the most pressing challenges is structural heart disease, particularly aortic stenosis — the narrowing of the aortic valve that restricts blood flow and can lead to heart failure. It is one of the most common and serious valve diseases in older adults.
Traditionally, treatment meant open-heart surgery to replace the diseased valve. While effective, the approach carries high risks and long recovery times, particularly in older patients.
Over the past two decades, transcatheter aortic valve replacement (TAVR) has revolutionised treatment by allowing minimally invasive procedures. Market leaders like Edwards Lifesciences Corp (NYSE:EW, ETR:EWL) and Medtronic PLC (NYSE:MDT, ETR:2M6) have made TAVR a mainstream therapy, but limitations remain. Biological tissue valves often deteriorate within a decade, and mechanical valves can require lifelong anticoagulation.
As a result, cardiologists and patients alike are searching for solutions that combine durability, natural blood flow dynamics, and minimal invasiveness.
Investors eye the next frontier
The structural heart device market represents one of the most attractive med-tech segments. Analysts forecast that TAVR procedures could double globally by the early 2030s, with Asia and emerging markets adding new growth layers to the mature US and European markets.
Hospitals are also under pressure to reduce costs and bed-days, making minimally invasive procedures financially attractive. Every day saved in hospital recovery is a win for strained healthcare systems.
Against this backdrop, smaller companies with breakthrough valve technologies have drawn investor attention. They represent both potential acquisition targets for major device players and long-term growth stories in their own right.
Anteris Technologies and a new class of valves
ASX- and Nasdaq-listed Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) is developing what it calls a new class of aortic valve designed to overcome the limitations of existing devices.
Its flagship product, the DurAVR™ transcatheter heart valve, is built on the company’s proprietary ADAPT® tissue technology. Unlike conventional valves, DurAVR is designed to mimic the natural three-dimensional geometry of a healthy human valve. The goal is to deliver more physiologic blood flow, reducing the turbulence that can damage red blood cells and contribute to valve failure.
Read more: Anteris Technologies delivers strong one-year results for DurAVR® Transcatheter Heart Valve
Early clinical data has been encouraging, with 130 patients now having received DurAVR globally, with one-year results showing zero prosthesis-patient mismatch (PPM) in small annuli patients — a key differentiator from current market leaders.
Anteris is preparing for a pivotal trial in Q3 2025, pending US Food and Drug Administration approval. Success could position the company to challenge incumbents and establish a foothold in the global market.
Proprietary biomaterials as a differentiator
At the core of Anteris’ strategy is its ADAPT® tissue technology, a biomaterial platform designed to eliminate the need for glutaraldehyde — the chemical treatment traditionally used in biological valves. Glutaraldehyde is associated with calcification and valve stiffening over time, which shortens durability.
By avoiding these issues, ADAPT® aims to produce tissue valves that last significantly longer, even in younger, more active patients. If successful, this could expand the use of tissue valves beyond older populations and further grow the addressable market.
Market dynamics and investor lens
The global heart valve market is already worth nearly US$15 billion and is projected to grow to US$40 billion by 2034. While Edwards and Medtronic dominate today, history shows that disruptive technologies can carve out meaningful share — particularly if they address durability concerns that remain unresolved.
For emerging med-tech companies like Anteris, the opportunity is significant, but so are the challenges. Clinical trials are expensive and lengthy, regulatory pathways are rigorous, and competing against giants will require strong data and strategic partnerships.
That said, the company represents a classic example of how small- and mid-cap biotechs can operate at the cutting edge of global healthcare problems. For investors looking at heart health as a theme, Anteris provides a direct play on the next wave of structural heart innovation.
The bigger picture
Cardiovascular disease may not always dominate biotech headlines, but it remains the largest and most persistent healthcare challenge worldwide. With ageing populations and rising healthcare costs, the demand for better, longer-lasting, and less invasive solutions is only increasing.
For investors, that makes heart health one of biotech’s quiet giants: a vast market where innovation still has room to transform outcomes and capture value.
Anteris Technologies is a case in point — a small company aiming to reshape the way we think about heart valves, with proprietary technology that could extend the life of replacement valves and improve patient quality of life. While the road ahead is complex, the prize on offer is equally significant.